Showing posts with label Estonia 2010. Show all posts
Showing posts with label Estonia 2010. Show all posts

Sunday, October 17, 2010

HIV activists help push tuberculosis awareness

Tallinn, Estonia: The call for a better, integrated approach to HIV and tuberculosis (TB) care has been getting louder worldwide in the past years. Equally, in terms of advocacy integration of the two diseases is gradually growing. People living with HIV speaking up on TB increasingly help put tuberculosis higher on the agenda. Read more


HIV and TB are the two deadliest infectious diseases globally, yet the attention given to and the awareness for the diseases remain largely unequal. Most of the spotlights are on HIV, not least because of strong activism for the disease. Advocacy for TB – though growing – remains much weaker. But TB's profile can be raised through the voices of those especially vulnerable to it: people living with HIV.

People who are HIV positive and infected with TB are 20 to 40 times more likely to develop active TB than people not infected with HIV. TB is a leading cause of death among people living with HIV, who have weakened immune systems. 
"Statistics show that especially in high burden countries people living with HIV are likely to get tuberculosis at least once in their lifetime. In some places co-infection is as high as 50% and mortality because of TB up to 60%," says Vivek Dharmaraj, project leader of Advocacy to Control TB Internationally (ACTION) Project / Global Health Advocates (GHA) India.

Engaging the HIV community is an area that ACTION/GHA has focused on. In India, they have worked extensively with the Indian Network for People living with HIV/AIDS (INP+) – a network of over 200,000 people in 24 states of India. "Advocacy is about education, empowerment and engagement," Dharmaraj explained at the sidelines of the Second Global Forum on TB Vaccines in Tallinn, Estonia, last month.

"Because this community is at such risk, they understand how serious TB is and how great the need is to have access to treatment. It is a matter of life and death," he continues. "TB is not easily diagnosed in the HIV patients; if undetected and not put on treatment early, tuberculosis can be quickly fatal in this co-infected condition. Apart from the need to know if they have TB, it becomes even more imperative that people living with HIV determine right at the start whether the tuberculosis is drug-resistant. As the community is educated and empowered in the area of tuberculosis they become engaged in advocacy. They can passionately advocate for better diagnostics tools, faster acting, less toxic drugs and vaccines."

"We have modules on TB, HIV-TB co-infection, treatment, what is freely available and then help them come to an understanding of what more is needed - diagnostics, drugs, etc," Dharmaraj says. "We encourage them to engage and advise their community, their local leaders, the politicians - who should be there for them. Not to blame but to go and share their knowledge and worries. They are often courageous and bold enough to speak up on TB as they have already taken the first step of coming out on their HIV status."

"HIV activists already deal with a lot of stigma," Claire Wingfield, TB/HIV project coordinator at TAG (Treatment Action Group) agrees. "And those with HIV/TB co-infection get the double stigma." In 2002 TAG, an HIV/AIDS research and policy think tank fighting for better treatment, a vaccine, and a cure for AIDS, included TB in its advocacy priorities because "we realized the people with HIV were at increased risk of developing and dying of TB." People living with HIV make loyal activists, Wingfield comments. "People get HIV for life, which means they are activists for life. When TB patients are cured, they are often no longer activists."

She sees the number of TB activists among people living with HIV growing. "It is great to see that for some TB is even their first issue now. They are absolutely raising the profile of TB. But it doesn’t have to be either TB or HIV. You can raise awareness for both, encourage discussion, make a difference."

Still, empowerment of TB patients has a long way to go, Wingfield stresses. "TB has such a public health approach, compared to the individual approach with HIV. There is not a lot of empowerment with information, neither among patients nor among health workers. The DOTS (Directly observed treatment, short-course) strategy is incredibly infantilizing, with people having to take medicine under observation of a healthcare worker. Where many HIV patients can exactly name their medicines, TB patients can often only say they take a yellow pill, a diamond shaped pill, etc. TB suffers from the white coat phenomenon: just take your medication because I said so."

"In India there has been some awareness among communities in the past few years. But some people still think TB is no longer a problem; that it is an old or only a poor person's disease or has even been eradicated," Dharmaraj of ACTION/GHA adds. "So a lot more has to be done to clear the air; we still need a bigger push to get the wider population involved more actively. We have to make sure to the disease is kept near the top of health agenda."

Wingfield hopes also activists from field other than HIV will increasingly address TB. "For mining communities, mother and child healthcare activists, labor unions, TB is a cross sector issue. It is important activists from other fields talk TB too."

Babs Verblackt - CNS(The author is a freelance journalist, a Fellow of CNS Writers' Bureau and Associate Communications atTuBerculosis Vaccine Initiative – TBVI) 


Published in:
Citizen News Service (CNS), India/Thailand 
The Asian Tribune, Sri Lanka/Thailand  
News Blaze News, California, USA
Elites TV News, USA
Now Public News, India
Topix News, Tallinn, Estonia 
All Voices News, Tallinn, Estonia
One News Page, India 
Bihar and Jharkhand News Service (BJNS) 
Tuberculosis Vaccine Initiative (TBVI)
Banderas News, Mexico 
Media For Freedom, Kathmandu, Nepal  
Healthdev.net
Keegy News, USA
Frankmacdonald.com, UK
News Now, UK
Thetvrealist.com  
Celebrifi.com   
Reddit.com  
Friendfeed.com                                                                                   

Wednesday, October 13, 2010

Comic book explains TB vaccine clinical trial

[To read the full comic book, click here]
TALLINN, ESTONIA: Finding participants for clinical trials is one of the challenges in the development of new vaccines against tuberculosis (TB). The South African Tuberculosis Vaccine Initiative (SATVI) recently launched a new means to reach out to communities where trials take place: a comic book. Read more

The 12-page comic book, printed in Afrikaans, Xhosa and English, aims to communicate information on TB vaccine clinical research in an entertaining and understandable way. Under the title ‘Carina’s Choice’ it tells the story of a young woman’s decision to enroll her baby daughter into a clinical trial for new TB vaccines. “Why did you do that?” a friend asks her on the cover, inside the answer follows.

The comic gives information on TB vaccine clinical trials and deals with common questions and misunderstandings on those trials in communities. Consultative focus group sessions with community stakeholders were held in the development of the comic, which helped shape among others the characterisation, setting, facts and community concerns that needed to be communicated, and language used.

“Many people in the community are not familiar with research,” explains SATVI co-director Hassan Mahomed, adding that levels of education and literacy are often low. “Regarding clinical trials, there is some superstition, many myths exist about e.g. taking blood, as well as ideas that people are used as guinea pigs, bad things will happen, or other negative attitudes. The comic deals with these thoughts, it explains what happens in trials. This way, we hope to increase knowledge and understanding.”

SATVI is conducting clinical trials in South-Africa for multiple novel TB vaccines. According to Mahomed, tuberculosis is widely known among communities, but not everybody is equally familiar with the need for new vaccines. The limitations of Bacille Calmette Guérin (BCG), the currently only available vaccine, are referred to in the comic book as well. Around 10,000 books have been printed, Stop TB Partnership funded the design. “The comics will be handed out through clinics, NGOs and at home visits,” Mahomed said at the sidelines of the Second Global Forum on TB Vaccines in Tallinn (September 21-24), Estonia.

The comic is a new tool for SATVI, which already works with e.g. posters, leaflets and DVDs explaining what clinical trials are all about. “Also through local media, radio, newspapers and NGOs we inform people about trials,” Mahomed adds. SATVI staff go out to communities, workplaces, schools, clinics and homes of newborns to contact and recruit people.

SATVI further works with a community advisory board (CAB) made of individuals from the community to represent the community’s interests in clinical trials. “They give advice to the researchers and input from the community. In every way it is very important to engage with communities”

SATVI staff and CAB members are also present in the comic book. It ends with a bill of rights for research participants. “It is all about informed consent,” Mahomed says. “At all times, even when people are participating already, they need to be constantly reminded of their rights and informed about the process of the trial.”

“We don’t know yet what impact the comic books will have,” he continues. “The comics will be handed out to groups of community members in different settings. After reading the comics, they will be engaged in focus group discussions to check understanding of the issues raised and also attitudes towards the comics themselves. Of course we hope the comic will have effect and improve understanding.”

The Worcester Senior Secondary, a local high school, has converted the comic book into a theatre play. This play was the centerpiece of the official launch of the book on October 9.

Babs Verblackt-CNS
(The author is a freelance journalist, a Fellow of CNS Writers' Bureau and Associate Communications atTuBerculosis Vaccine Initiative – TBVI)  


Published in:
Central Chronicle,  Madhya Pradesh, India
Modern Ghana News, Accra, Ghana
Citizen News Service (CNS), India/Thailand 
Lankan News Headline, Sri Lanka    
The Asian Tribune, Sri Lanka/Thailand 
The Nigerian Voice, Nigeria  
Banderas News, Mexico
Elites TV News, USA
Bihar and Jharkhand News Service (BJNS) 
The Nigerian Voice, Nigeria 
Tuberculosis Vaccine Initiative (TBVI)
SATVI, South Africa 
News Trust News, USA 
Healthdev.net
Allvoice.com
Celebrifi.com
Hivatlas.org      

Topixnews.com      
Friendfeed.com  
Comicmovie.com                                               

Sunday, October 3, 2010

CNS coverage from 2nd Global Forum on Tuberculosis (TB) Vaccines, Tallinn, Estonia

Babs Verblackt wrote on issues around the tuberculosis (TB) vaccines, on-site from the 2nd Global Forum on TB Vaccines, in Tallinn, Estonia (21-24 September 2010). Babs is freelance journalist, a Fellow of CNS Writers' Bureau and Associate Communications at TuBerculosis Vaccine InitiativeTBVI). Read more



These CNS articles were published in a diverse range of media outlets of many countries including: India, Pakistan, Thailand, Sri Lanka, Nepal, Brunei Darussalam, Ghana, United Arab Emirates (UAE), USA, New Zealand, Bangladesh, South Korea, among others. CNS also used social media extensively to disseminate articles through Twitter (3000+), Facebook (2600+), younews, reddit, Google Buzz, Digg, newstrust, HealthDev.net, AIDSspace, nowpublic and others. These articles were also disseminated via electronic discussion forums on specific issues like SEA-AIDS, Stop-TB, Lung Health, to name a few. Synopsis of these articles was translated in Thai language and broadcasted through FM 102.5 in Thailand.

Five CNS articles written by Babs Verblackt, from the 2nd Global Forum for TB Vaccines are as follows:

Thanks

Thursday, September 30, 2010

Clinical trial capacity remains challenge for TB vaccine development

Tallinn, Estonia: While progress is being made in the development of new vaccines against tuberculosis (TB), sufficient clinical trial capacity remains a major challenge, researchers reaffirmed at the Second Global Forum on TB Vaccines in Tallinn, Estonia (21-24 September 2010). Read more



Scientists from around the world presented the latest developments in their research on new TB vaccines. Eight vaccine candidates were presented, which are now all tested on humans in various stages of clinical trials, many in Africa. Currently the most advanced vaccine candidate is the MVA85A vaccine developed by Oxford University.

While the current TB vaccine candidates have shown promising early-stage results on safety and immunogenicity in studies conducted at well-established world class TB vaccine research sites, further tests are required and additional clinical trial sites will be needed to meet the demand. The already long and complicated process of testing vaccines is made more challenging by a general lack of capacity for clinical trials worldwide, the researchers acknowledged.

"It is important to involve local communities from the very beginning," stressed Dr Tom Evans, MD, Chief Scientific Officer at Aeras Global TB Vaccine Foundation in a presentation.

Evans mentioned the need to address language issues, local (traditional) medical practices, local perceptions about giving blood and participating in clinical trials as necessary steps needed to avoid possible pitfalls. But even logistical problems such as power grid problems and limited access to electronic data, or unexpected situations such as worldwide travel problems and instability of governments can influence the course of clinical trials.

According to Robert Nakibumba, Community Representative to the New Vaccines Working Group at Stop TB Partnership, creating 'minds for a new TB vaccine' on community level is a challenge as well. "Many people think: there is a TB vaccine already, why you come up with a new vaccine?" he said in a later session at the meeting. "We have to tactfully explain to the community the limitations of BCG, they must know the existing tool is not effective."

BCG (Bacille Calmette Guérin) is the only currently available vaccine against TB. It is widely used around the globe and protective against severe forms of TB in children. But it is not effective enough against pulmonary TB in adolescents and adults, the most common and most infective form of TB worldwide.

Nakibumba also underlined the importance of involving local communities. "They are not only patients or participants in clinical trials. They are going to get the vaccine, they are serious stakeholders."

The Second Global Forum on TB Vaccines in Tallinn, Estonia, last week brought together around 200 scientists, clinicians, manufacturers, NGOs and governmental institutions from around the world. They reviewed the progress made in vaccine development in the past decade and look forward to the challenges and opportunities ahead.


Babs Verblackt - CNS
(The author is a freelance journalist, a Fellow of CNS Writers' Bureau and Associate Communications at TuBerculosis Vaccine InitiativeTBVI


Published in: 
News Blaze News, California, USA      
The Asian Tribune, Sri Lanka/Thailand
Modern Ghana News, Accra, Ghana
Elites TV News, USA  
Citizen News Service (CNS), India/Thailand 
Scoop World Independent News, New Zealand
All voices News, India  
Now Public News, India
Bihar and Jharkhand News Service (BJNS)
Lankan News Headline, Sri Lanka
Topix News, India
Banderas News, Mexico
Blitzquotidiano.com, Tallinn, Estonia 
The Nigerian Voice, Nigeria 
Healthdev.net.org
Silobreaker.com
Iplextra.indiatimes.com  
Sec.wltx.com   
Enews18.com   
Soccer.msg.com   
Feedraider.com   
Friendfeed.com  
Iplextra.indiantimes.com        
Touristlinks.com    

Wednesday, September 22, 2010

TB doesn't get the prioritization it needs

Tallinn, Estonia: Tuberculosis (TB) is considered a major public health issue by decision makers, yet commonly doesn't get the place of importance it needs as a health care priority. These are the preliminary results of a study presented at the Second Global Forum on TB Vaccines in Tallinn, Estonia, on Wednesday, 22 September 2010. Read more



The market research study provides an overview of national-level decision makers’ views on the introduction of new vaccines against TB. Undertaken in eight countries with high TB burdens, researchers conducted 86 one-on-one interviews (45-60 minutes) with senior Ministry of Health (MoH) civil servants responsible for vaccine introduction, MoH technical experts involved in delivering vaccines through the Expanded Programme on Immunization, senior Ministry of Finance (MoF) civil servants responsible for health budgets, senior public health clinicians, (children’s) health related NGOs, parliamentarians, and senior journalists. The study was conducted in China, India, South-Africa, Brazil, Russia, Mozambique, Cambodia and Romania.

The interviewees were presented with three hypothetical scenarios for new TB vaccines and asked questions about, among others, the likely demand and likelihood of rapid implementation. Overall, there was enthusiasm for (the use of) a new TB vaccine. "We still need to further analyze and break down the results, but generally they are encouraging," said Lew Barker, Senior Medical Advisor with the Aeras Global TB Vaccine Foundation. "What is striking is that the answers varied both within and between countries, ranging from positive to negative, and often with a wait and see attitude."

When the interviewees were initially asked about their country's major public healthcare priorities, none mentioned TB. Rather issues such as primary healthcare, mother and childcare, chronic diseases and HIV/AIDS topped the lists. "But if they were then asked about TB, the respondents immediately acknowledged it is a big problem that doesn't get the attention it deserves," Barker explained. "So TB is not at the top of their mind but it definitely is there on a lower level. It is a neglected disease - we already know that - that is one of the challenges the fight against TB has to face."

The results further showed a widespread dissatisfaction with the only currently available vaccine, Bacille Calmette Guérin (BCG). The vaccine is protective against severe forms of TB in children, but not effective enough against lung TB in adolescents and adults, the most common and most infective form of TB worldwide.

The market research study titled 'Barriers and Drivers for Introduction of New TB Vaccines' was done as part of a broader initiative of the Stop TB Partnership's Task Force on Economics and Product Profiles for New TB Vaccines. It will be published online later this year.

At the international conference in Tallinn, around 200 scientists, clinicians, manufacturers, NGOs and governmental institutions from around the world this week (September 21-24) review the progress made in vaccine development in the past decade and look forward to the challenges and opportunities ahead.

Babs Verblackt-CNS
(The author is a freelance journalist, a Fellow of CNS Writers' Bureau and Associate Communications at TuBerculosis Vaccine InitiativeTBVI


Published in:     
The Zimbabwe Telegraph, Zimbabwe  
Modern Ghana News, Accra, Ghana
Citizen News Service (CNS), India/Thailand 
Elites TV News, USA
Banderas News, Mexico
The Nigerian Voice, Nigeria
Now Public News, India 
Topix News, Tallinn, Estonia  
New Zim Situation, Zimbabwe 
One News Page, Tallinn, Estonia
Tuberculosis Vaccine Initiatives (TBVI)
Bihar and Jharkhand News Service (BJNS)
Oneclick.indiatimes.com          
Twitter.com      
Connect.in.com                                                     

Tuesday, September 21, 2010

New effective TB vaccine would be 'game changer'

Tallinn, Estonia: Despite progress made in recent years, tuberculosis (TB) remains a challenge for the world, participants heard at the special opening session of the Second Global Forum on TB Vaccines in Tallinn, Estonia. New vaccines could make a significant difference. Read more



Christopher Dye of the World Health Organization in Geneva pointed out that treatment success and case detection has shown tremendous improvement in the past decades. "The TB incidence rate is going down, but the problem is that it is going down slowly," Dye explained. "The dominant reason for the lack of success is persistent transmission," he said, referring to the difficulties of diagnosing patients promptly within weak health systems.

Dye underlined that various new tools are needed in the fight against TB. But if there would be a new vaccine it would "really change the game", he emphasized. "It would have a big impact and shift the emphasis from cure to prevention," Dye said, stating that he sees reasons to be hopeful a vaccine can be found.

Also Peter Small, Senior Program Officer for TB at the Bill & Melinda Gates Foundation, called an effective new vaccine a 'game changer' that would 'revolutionize the fight against TB'. "An effective TB vaccine would fundamentally transform the strategy for global TB control and permanently change the trajectory of the epidemic," Small said, emphasizing increased funding and commitment will be critical to continue progress in TB vaccine research and development. "Government and philanthropy must do their part, but so must leading biotech and pharmaceutical companies around the globe."

"Vaccines are the best buy in public health - we believe strongly in the power of vaccines to improve health and save lives," he said. "Childhood vaccines are modern miracles - for just a few dollars per child they prevent death and disease for a lifetime. They are also a smart, long-term investment - immunizations give kids a shot at a healthy, productive life and healthy children lead to healthier families and more self sufficient communities and countries."

Scientists, clinicians, manufacturers, NGOs and governmental institutions from around the world this week will review the progress made in vaccine development in the past decade and look forward to the challenges and opportunities ahead. Tallinn has been selected as the venue for the meeting as TB is a significant health problem in Estonia, yet the country has been successful in the fight against the airborne infectious disease.

"We have seen good results but we need to go further," Hanno Pevkur, Estonian minister of Social Affairs, said at the opening session. "Multidrug resistance is our biggest problem, but also TB/HIV co-infection as well as TB and alcohol abuse. We have to look at the future and have special programs."

"We have different problems," Piret Viiklepp, head of the Estonian Tuberculosis Registry and special guest at the conference, agrees. "And if we want to reduce TB we have to work with all problems."

According to her political commitment has made a difference in the country. "All treatment is free of charge, but only under DOTS (directly observed treatment, short-course). You can't just be treated by your doctor or go to the pharmacy and ask for TB drugs. You have to go through DOTS programs. That way we also hope to prevent multidrug-resistant (MDR) TB from spreading."

The Second Global Forum on TB Vaccines, with around 200 participants one of the largest TB vaccine gatherings for a decade, will continue until September 24.


Babs Verblackt-CNS
(The author is a freelance journalist, a Fellow of CNS Writers' Bureau and Associate Communications at TuBerculosis Vaccine Initiative – TBVI) 


Published in:
Citizen News Service (CNS), India/Thailand  
Pakistan Christian Post, Karachi, Pakistan
Modern Ghana News, Accra, Ghana 
News Blaze News, California, USA
Now Public News, India 
Topix News, Tallinn, Estonia
Banderas News, Mexico 
Tuberculosis Vaccine Initiative (TBVI) 
Bihar and Jharkhand News Service (BJNS)
HealthDev.net.org
Oneclick.indiatimes.com
Beritneyspearswatcher.com
Care2.com   
Sec.wltx.com      
Iplextra.indiatimes.com   
Feedraider.com      
Reddit.com